Ahead of its business plan, Andera Partners approaches 4 billion euros in assets under management and announces a new 2028 target of 6 to 8 billion euros

Newron reports striking one-year interim efficacy results from its Phase II clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia

Mainz Biomed expands european commercial footprint and enters markets in Spain and UK

Abivax to present blood and rectal tissue data from UC patients treated with obefazimod at the 18th Congress of ECCO

Andera Partners portfolio company Mineralys Therapeutics successfully completes upsized $192 million Nasdaq IPO

TVM Capital Life Science Announces creation of LAmAb Biologics to develop innovative preventative therapy for allergy patients

Spexis and SPRIM Global Investments (SGI) announce plans for clinical trial partnership to fund up to half of the projected Phase 3 clinical development costs of ColiFin®

Carbios appoints four new Board members to strengthen international expertise in brand development, business growth and scientific research

TVM Capital Life Science announces up to USD 24 million investment in oncology company, Recurv Pharma, Inc.

Adrenomed appoints Dr. Stephan Witte as Chief Medical Officer